文献速递心力衰竭与心肌病

窦性心律心力衰竭患者的抗凝治疗:系统综述与荟萃分析

Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis.
PubMed 文献 · Heart · 2019-04-08

该系统综述与荟萃分析纳入5项符合预设检索标准的随机对照试验,比较抗凝治疗与抗血小板、安慰剂或对照治疗对射血分数降低的心力衰竭(HFrEF)且为窦性心律患者临床结局的影响。结果显示抗凝未降低全因死亡、心衰再住院或非致死性心肌梗死,虽减少非致死性卒中,但被大出血增加所抵消。

要点

  • 窦性心律HFrEF患者抗凝不降低全因死亡与心衰再住院风险。
  • 抗凝使非致死性卒中减少(RR 0.63),但大出血增加(RR 1.88)。
  • 不支持血栓栓塞在HFrEF发病与死亡中起重要作用的假说。

核心结论

  • 在窦性心律的HFrEF患者中,抗凝治疗未改善全因死亡、心衰再住院及非致死性心肌梗死结局。
  • 抗凝虽降低非致死性卒中发生率,但大出血发生率升高,二者相互抵消。
  • 该荟萃分析结果不支持血栓或栓塞在HFrEF致病与死亡中起重要作用的假说,卒中相关疾病负担除外。

研究设计与样本

  • 更新版系统综述与荟萃分析,纳入5项符合预设检索标准的随机对照试验。
  • 比较随机接受抗凝治疗者与随机接受抗血小板治疗、安慰剂或对照治疗者。

主要发现

  • 与对照治疗相比,抗凝未降低全因死亡(RR 0.99,95%CI 0.90至1.08)。
  • 抗凝未降低心衰(再)住院(RR 0.97,95%CI 0.82至1.13)。
  • 抗凝未降低非致死性心肌梗死(RR 0.92,95%CI 0.75至1.13)。
  • 抗凝降低非致死性卒中(RR 0.63,95%CI 0.49至0.81,p=0.001)。
  • 抗凝增加大出血发生(RR 1.88,95%CI 1.49至2.38,p=0.001)。

临床怎么用

  • 对窦性心律的HFrEF患者,不应仅以降低死亡或心衰住院为目的常规启动抗凝治疗。
  • 决策时需权衡非致死性卒中减少与大出血增加的净获益,个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Heart failure is a prothrombotic state, and it has been hypothesised that thrombosis and embolism cause non-fatal and fatal events in heart failure and reduced ejection fraction (HFrEF). We sought to determine the effect of anticoagulant therapy on clinical outcomes in patients with HFrEF who are in sinus rhythm. METHODS: We conducted an updated systematic review and meta-analysis to examine the effect of anticoagulation therapy in patients with HFrEF in sinus rhythm. Our analysis compared patients randomised to anticoagulant therapy with those randomised to antiplatelet therapy, placebo or control, and examined the endpoints of all-cause mortality, (re)hospitalisation for worsening heart failure, non-fatal myocardial infarction, non-fatal stroke of any aetiology and major haemorrhage. RESULTS: Five trials were identified that met the prespecified search criteria. Compared with control therapy, anticoagulant treatment did not reduce all-cause mortality (risk ratio [RR] 0.99, 95% CI 0.90 to 1.08), (re)hospitalisation for heart failure (RR 0.97, 95% CI 0.82 to 1.13) or non-fatal myocardial infarction (RR 0.92, 95% CI 0.75 to 1.13). Anticoagulation did reduce the rate of non-fatal stroke (RR 0.63, 95% CI 0.49 to 0.81, p=0.001), but this was offset by an increase in the incidence of major haemorrhage (RR 1.88, 95% CI 1.49 to 2.38, p=0.001). CONCLUSIONS: Our meta-analysis provides evidence to oppose the hypothesis that thrombosis or embolism plays an important role in the morbidity and mortality associated with HFrEF, with the exception of stroke-related morbidity.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Beggs SAS, Rørth R, Gardner RS, et al. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart. 2019. PMID: 30962190. doi:10.1136/heartjnl-2018-314381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。